Related Experiment Video
Updated: Sep 5, 2025

Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Metallated phthalocyanines and their hydrophilic derivatives for multi-targeted oncological photodynamic therapy
Lionel Mendes Dias1, Mark J de Keijzer2, Daniël Ernst3
1Jiaxing Key Laboratory for Photonanomedicine and Experimental Therapeutics, Department of Pharmaceutics, College of Medicine, Jiaxing University, Jiaxing, Zhejiang, PR China; CICS-UBI, Health Sciences Research Center, University of Beira Interior, Covilhã, Portugal; Department of Medical Biology, Cancer Center Amsterdam, Amsterdam UMC Location Academic Medical Center, Amsterdam, the Netherlands; Laboratory of Experimental Oncology, Department of Pathology, Erasmus MC, Rotterdam, the Netherlands.
Background And Aim:
A photosensitizer (PS) delivery and comprehensive tumor targeting platform was developed that is centered on the photosensitization of key pharmacological targets in solid tumors (cancer cells, tumor vascular endothelium, and cellular and non-cellular components of the tumor microenvironment) before photodynamic therapy (PDT). Interstitially targeted liposomes (ITLs) encapsulating zinc phthalocyanine (ZnPC) and aluminum phthalocyanine (AlPC) were formulated for passive targeting of the tumor microenvironment. In previous work it was established that the PEGylated ITLs were taken up by cultured cholangiocarcinoma cells. The aim of this study was to verify previous results in cancer cells and to determine whether the ITLs can also be used to photosensitize cells in the tumor microenvironment and vasculature. Following positive results, rudimentary in vitro and in vivo experiments were performed with ZnPC-ITLs and AlPC-ITLs as well as their water-soluble tetrasulfonated derivatives (ZnPCS4 and AlPCS4) to assemble a research dossier and bring this platform closer to clinical transition.
Methods:
Flow cytometry and confocal microscopy were employed to determine ITL uptake and PS distribution in cholangiocarcinoma (SK-ChA-1) cells, endothelial cells (HUVECs), fibroblasts (NIH-3T3), and macrophages (RAW 264.7). Uptake of ITLs by endothelial cells was verified under flow conditions in a flow chamber. Dark toxicity and PDT efficacy were determined by cell viability assays, while the mode of cell death and cell cycle arrest were assayed by flow cytometry. In vivo systemic toxicity was assessed in zebrafish and chicken embryos, whereas skin phototoxicity was determined in BALB/c nude mice. A PDT efficacy pilot was conducted in BALB/c nude mice bearing human triple-negative breast cancer (MDA-MB-231) xenografts.
Results:
The key findings were that (1) photodynamically active PSs (i.e., all except ZnPCS4) were able to effectively photosensitize cancer cells and non-cancerous cells; (2) following PDT, photodynamically active PSs were highly toxic-to-potent as per anti-cancer compound classification; (3) the photodynamically active PSs did not elicit notable systemic toxicity in zebrafish and chicken embryos; (4) ITL-delivered ZnPC and ZnPCS4 were associated with skin phototoxicity, while the aluminum-containing PSs did not exert detectable skin phototoxicity; and (5) ITL-delivered ZnPC and AlPC were equally effective in their tumor-killing capacity in human tumor breast cancer xenografts and superior to other non-phthalocyanine PSs when appraised on a per mole administered dose basis.
Conclusions:
AlPC(S4) are the safest and most effective PSs to integrate into the comprehensive tumor targeting and PS delivery platform. Pending further in vivo validation, these third-generation PSs may be used for multi-compartmental tumor photosensitization.
Insights
Aluminum phthalocyanines (AlPCs) show promise as safe and effective photosensitizers for photodynamic therapy (PDT). These compounds, delivered via interstitially targeted liposomes (ITLs), demonstrated potent tumor cell killing with minimal systemic toxicity, paving the way for advanced cancer treatment.
Area of Science:
- Nanomedicine and Drug Delivery
- Photodynamic Therapy (PDT)
- Cancer Therapeutics
Background:
- Development of a photosensitizer (PS) delivery platform for comprehensive tumor targeting before photodynamic therapy (PDT).
- Formulation of interstitially targeted liposomes (ITLs) encapsulating zinc phthalocyanine (ZnPC) and aluminum phthalocyanine (AlPC) for passive tumor microenvironment targeting.
- Previous studies confirmed ITL uptake by cholangiocarcinoma cells; this study aimed to verify these findings and assess ITL photosensitization of tumor microenvironment and vasculature.
Purpose of the Study:
- To verify previous findings on ITL uptake in cancer cells.
- To determine if ITLs can photosensitize cells within the tumor microenvironment and vasculature.
- To evaluate the safety and efficacy of ZnPC- and AlPC-based ITLs for potential clinical translation.
Main Methods:
- Utilized flow cytometry and confocal microscopy to assess ITL uptake and PS distribution in various cell types (cancer, endothelial, fibroblasts, macrophages).
- Verified endothelial cell uptake under flow conditions.
- Assessed dark toxicity, PDT efficacy, cell death mechanisms, and cell cycle arrest via cell viability assays and flow cytometry. Evaluated systemic and skin phototoxicity in animal models (zebrafish, chicken embryos, mice) and conducted a pilot PDT efficacy study in breast cancer xenografts.
Main Results:
- Photodynamically active PSs effectively photosensitized both cancer and non-cancerous cells, exhibiting high potency post-PDT.
- No significant systemic toxicity was observed in zebrafish and chicken embryos.
- ITL-delivered AlPC(S4) showed no detectable skin phototoxicity, unlike ZnPC variants. Both ZnPC and AlPC ITLs demonstrated comparable and superior tumor-killing efficacy in xenografts compared to other PSs on a per-mole basis.
Conclusions:
- Aluminum phthalocyanine derivatives (AlPC(S4)) are identified as the safest and most effective PSs for the developed tumor targeting and delivery platform.
- These third-generation PSs hold potential for multi-compartmental tumor photosensitization.
- Further in vivo validation is recommended pending clinical transition.
More Related Videos
11:04An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model
Published on: January 13, 2023
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016